Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
Enzo Bonora, Juan P. Frías, Francisco J. Tinahones, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 10, pp. 2242-2250
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
Silva Arslanian, Tamara S. Hannon, Philip Zeitler, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 5, pp. 433-443
Open Access | Times Cited: 88
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S181-S206
Closed Access | Times Cited: 59
Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?
Simon Kloock, Christian G. Ziegler, Ulrich Dischinger
Pharmacology & Therapeutics (2023) Vol. 251, pp. 108549-108549
Open Access | Times Cited: 51
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 18
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
Xueqin Gao, Xiaoli Hua, Xu Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 53
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
Maurício Reis Pedrosa, Denise Reis Franco, Hannah Waisberg Gieremek, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 11, pp. 867-884
Closed Access | Times Cited: 47
Decreased Risk of Readmission and Complications With Preoperative GLP-1 Analog Use in Patients Undergoing Primary Total Joint Arthroplasty
Anirudh Buddhiraju, Whitney Kagabo, Harpal S. Khanuja, et al.
The Journal of Arthroplasty (2024) Vol. 39, Iss. 12, pp. 2911-2915.e1
Closed Access | Times Cited: 10
Exploring the therapeutic potential of GLP-1 receptor agonists in the management of obstructive sleep apnea: a comprehensive review
Amruth Akhil Alluri, Matthew Kurien, Nikhil Patel Pokar, et al.
Journal of Basic and Clinical Physiology and Pharmacology (2025)
Closed Access | Times Cited: 1
360-Degree Perspectives on Obesity
Magdalena Cuciureanu, Cătălin-Cezar Caratașu, Levon Gabrielian, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1119-1119
Open Access | Times Cited: 21
GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy?
Georgios S. Papaetis
Archives of Medical Science - Atherosclerotic Diseases (2023) Vol. 8, Iss. 1, pp. 19-34
Open Access | Times Cited: 19
Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting
Ying Hu, Shuilian Zheng, Xiaolan Ye, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 3, pp. 152-152
Open Access | Times Cited: 24
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes
Christophe De Block, Eveline Dirinck, Ann Verhaegen, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 5, pp. 788-805
Closed Access | Times Cited: 23
GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons
Georgios S. Papaetis, Angelos Kyriacou
Advances in Clinical and Experimental Medicine (2022) Vol. 31, Iss. 11, pp. 1265-1274
Open Access | Times Cited: 20
Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
Andrew Overholser, Eric J. Czech, Linda Speer, et al.
Translation The University of Toledo Journal of Medical Sciences (2025) Vol. 13, Iss. 1
Open Access
Trends, Demographics, and Outcomes for Glucagon-Like Peptide-1 Receptor Agonist Use in Total Knee Arthroplasty: An 11-Year Perspective
Jonathan Katzman, Muhammad Ammar Haider, Casey Cardillo, et al.
The Journal of Arthroplasty (2025)
Closed Access
Glycemic Targets and Prevention of Complications
Yumiko Tsushima, Nicholas R. Galloway
The Journal of Clinical Endocrinology & Metabolism (2025) Vol. 110, Iss. Supplement_2, pp. S100-S111
Closed Access
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS‐1 to ‐5 studies
Ildiko Lingvay, Alice Cheng, Joshua A. Levine, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 4, pp. 965-974
Open Access | Times Cited: 18
Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
Keith C. Ferdinand, Julia P. Dunn, Claudia Nicolay, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 10
A growth-differentiation factor 15 receptor agonist in randomized placebo-controlled trials in healthy or obese persons
William B. Smith, D. Le Nguyen, Timothy M. Clough, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 3
ANTI-OBESITY MEDICATIONS IN ADULT AND PEDIATRIC OBESITY AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Natalie Rodríguez, Phillipp Hartmann
Pharmacological Reviews (2025), pp. 100058-100058
Open Access
Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022
Suzanne Cuda, Marisa Censani, Roohi Y. Kharofa, et al.
Obesity Pillars (2022) Vol. 4, pp. 100048-100048
Open Access | Times Cited: 16
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase
José Seijas‐Amigo, Ángel Salgado‐Barreira, Rosana Castelo-Dominguez, et al.
Primary care diabetes (2023) Vol. 17, Iss. 4, pp. 366-372
Open Access | Times Cited: 8
GLP-1 RA Improves Diabetic Retinopathy by Protecting the Blood-Retinal Barrier through GLP-1R-ROCK-p-MLC Signaling Pathway
Liufeng Wei, Weiwei Mo, Shanshan Lan, et al.
Journal of Diabetes Research (2022) Vol. 2022, pp. 1-14
Open Access | Times Cited: 14
Dulaglutide Improves Gliosis and Suppresses Apoptosis/Autophagy Through the PI3K/Akt/mTOR Signaling Pathway in Vascular Dementia Rats
Tianyuan Guan, Yining Xiao, Xiaohua Xie, et al.
Neurochemical Research (2022) Vol. 48, Iss. 5, pp. 1561-1579
Closed Access | Times Cited: 13
GLP‐1 agonists for people living with HIV and obesity, is there a potential?
Leena Zino, Cees J. Tack, Olivier Richel, et al.
HIV Medicine (2023) Vol. 24, Iss. 10, pp. 1029-1034
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top